In 2020, Globocan reported over 400,000 new corpus uteri cases, with Asia accounting for about 40% of these new cases. China, where EC is the third most common female malignancy, accounted for nearly half of the new cases in Asia.
Novotech 入圍 2023 年亞太細胞和基因療法 CRO 卓越獎決賽
新加坡, July 14, 2023 -- 以亞太區為中心,擁有全球營運能力的生物科技 CRO 領導者 Novotech,成為 2023
報告